Patents Assigned to LABORATORIOS SILANES S.A. DE C.V.
-
Patent number: 11951081Abstract: The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed.Type: GrantFiled: November 2, 2021Date of Patent: April 9, 2024Assignee: LABORATORIOS SILANES S.A. DE C.V.Inventor: Jorge González-Canudas
-
Patent number: 11510886Abstract: The present invention relates to metformin amino acid compounds (SLNs), pharmaceutical compositions thereof, and methods of using them for the treatment of hyperglycemia, diabetes, and Type 2 diabetes. The compounds can be synthesized using the processes disclosed herein.Type: GrantFiled: September 29, 2017Date of Patent: November 29, 2022Assignee: LABORATORIOS SILANES, S.A. DE C.V.Inventor: Jorge González-Canudas
-
Patent number: 11185516Abstract: The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed.Type: GrantFiled: September 29, 2017Date of Patent: November 30, 2021Assignee: Laboratorios Silanes S.A. DE C.V.Inventor: Jorge González-Canudas
-
Publication number: 20200165331Abstract: The present invention relates to a novel vNAR protein of SEQ ID No: 1 capable of inhibiting the activity of VEGF in carnivorous mammals of the Canis and Felis genera, thereby inhibiting solid tumors growth of both genres.Type: ApplicationFiled: April 20, 2018Publication date: May 28, 2020Applicants: CENTRO DE INVESTIGACIÓN CIENTÍFICA Y DE EDUCACIÓN SUPERIOR DE ENSENADA, BAJA CALIFORNIA, LABORATORIOS SILANES, S.A. DE C.V., TERACLÓN IDF, NOVA PROTEINS S.A. DE C.V.Inventors: Alexei Fedorovish LICEA NAVARRO, Dalia Vanessa MILLÁN GÓMEZ, Liliana Noemi SÁNCHEZ CAMPOS, Carolina ELOSUA PORTUGAL, Jorge Fernando PANIAGUA SOLÍS, Salvador DUEÑAS ESPINOZA
-
Patent number: 9683035Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: GrantFiled: July 25, 2016Date of Patent: June 20, 2017Assignee: LABORATORIOS SILANES, S.A. DE C.V.Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Patent number: 8703183Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.Type: GrantFiled: December 24, 2010Date of Patent: April 22, 2014Assignee: Laboratorios Silanes S.A. de C.V.Inventor: Jose Manuel FranciscoOchoa Lara
-
Publication number: 20140044716Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: ApplicationFiled: July 17, 2013Publication date: February 13, 2014Applicant: LABORATORIOS SILANES, S.A. DE C.V.Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Lícea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Patent number: 8541551Abstract: The invention relates to the isolation, characterization and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti., L. reclusa and L. laeta, and the toxoids thereof. The invention also relates to the production of active sphingomyelinases D and the toxoids thereof using recombinant means and to the use of same as an immunogen for the production in vertebrates of antibodies that neutralize the corresponding venom and the respective fragments F(ab?)2. The invention further relates to the use of recombinant sphingomyelinases D as part of an antigen matrix which can be used in the immunopurification of antibodies and the fragments thereof or as part of any diagnostic device used to obtain clinical confirmation that the causal agent of poisoning in a patient is a spider of the Loxosceles genus.Type: GrantFiled: September 11, 2012Date of Patent: September 24, 2013Assignees: Universidad Nacional Autonoma de Mexico, Laboratorios Silanes S.A. de C.V.Inventors: Alejandro Olvera Rodriguez, Roberto Pablo Stock Silberman, Blanca Margarita Ramos Cerrillo, Rosana Sanchez-Lopez, Alejandro Alagon Cano
-
Patent number: 8496933Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: GrantFiled: November 4, 2010Date of Patent: July 30, 2013Assignee: Laboratorios Silanes, S.A. de C.V.Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Publication number: 20130071399Abstract: The invention relates to the isolation, characterisation and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti., L. reclusa and L. laeta, and the toxoids thereof. The invention also relates to the production of active sphingomyelinases D and the toxoids thereof using recombinant means and to the use of same as an immunogen for the production in vertebrates of antibodies that neutralise the corresponding venom and the respective fragments F(ab?)2. The invention further relates to the use of recombinant sphingomyelinases D as part of an antigen matrix which can be used in the immunopurification of antibodies and the fragments thereof or as part of any diagnostic device used to obtain clinical confirmation that the causal agent of poisoning in a patient is a spider of the Loxosceles genus.Type: ApplicationFiled: September 11, 2012Publication date: March 21, 2013Applicants: Laboratorios Silanes S.A. DE C.V., Universidad Nacional Autonoma De MexicoInventors: Alejandro Olvera Rodriguez, Roberto Pablo Stock Silberman, Blanca Margarita Ramos Cerrillo, Rosana Sanchez-Lopez, Alejandro Alagon Cano
-
Patent number: 8287860Abstract: The invention relates to the isolation, characterization and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti, L reclusa and L. laeta, and the toxoids thereof. The invention also relates to the production of active sphingomyelinases D and the toxoids thereof using recombinant means and to the use of same as an immunogen for the production in vertebrates of antibodies that neutralise the corresponding venom and the respective fragments F(ab?)2. The invention further relates to the use of recombinant sphingomyelinases D as part of an antigen matrix which can be used in the immunopurification of antibodies and the fragments thereof or as part of any diagnostic device used to obtain clinical confirmation that the causal agent of poisoning in a patient is a spider of the Loxosceles genus.Type: GrantFiled: August 29, 2005Date of Patent: October 16, 2012Assignee: Universidad Nacional Autonoma de Mexico and Laboratorios Silanes S.A. de C.V.Inventors: Alejandro Olvera Rodriguez, Roberto Pablo Stock Silberman, Blanca Margarita Ramos Cerrillo, Rosana Sanchez-Lopez, Alejandro Alagon Cano
-
Publication number: 20110177078Abstract: The invention relates to the isolation, characterisation and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti, L reclusa and L. laeta, and the toxoids thereof. The invention also relates to the production of active sphingomyelinases D and the toxoids thereof using recombinant means and to the use of same as an immunogen for the production in vertebrates of antibodies that neutralise the corresponding venom and the respective fragments F(ab?)2. The invention further relates to the use of recombinant sphingomyelinases D as part of an antigen matrix which can be used in the immunopurification of antibodies and the fragments thereof or as part of any diagnostic device used to obtain clinical confirmation that the causal agent of poisoning in a patient is a spider of the Loxosceles genus.Type: ApplicationFiled: August 29, 2005Publication date: July 21, 2011Applicants: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO, LABORATORIOS SILANES S.A. DE C.V.Inventors: Alejandro Olvera Rodriguez, Roberto Pablo Stock Silberman, Blanca Margarita Ramos Cerrillo, Rosana Sanchez-Lopez, Alejandro Alagon Cano
-
Publication number: 20110129473Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: ApplicationFiled: November 4, 2010Publication date: June 2, 2011Applicant: Laboratorios Silanes, S.A. de C.V.Inventors: JORGE F. PANIAGUA-SOLÍS, María Teresa MATA-GONZÁLEZ, Walter J. GARCÍA-UBBELOHDE, Araceli OLGUÍN-JIMENEZ, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Publication number: 20070264331Abstract: This invention is directed to a pharmaceutical composition in the form of a tablet with improved stability, as well as the process for obtaining said composition. The tablet of the present invention comprises two active ingredients comprising two oral hypoglycemic agents: one phase with a sulphonylurea, such as immediate release Glimepiride, and a second phase with a biguanide, such as extended-release Metformin hydrochloride (Metformin HCl). The biphasic tablet, which can include over 500 mg of Metformin HCl (i.e. up to 1,000 or 1,500 mg, depending on the daily requirements of each patient), is to be orally administered once or twice a day. The combination of these hypoglycemic agents has a synergic effect and therefore a greater effectiveness in controlling the blood glucose level in patients with diabetes mellitus, type 2.Type: ApplicationFiled: September 8, 2006Publication date: November 15, 2007Applicant: Laboratorios Silanes, S.A de C.V.Inventors: Antonio Regalado, Sixto Serafin Leon
-
Publication number: 20070213324Abstract: The present invention provides a pharmaceutical composition or formulation in the form of tablets of proved stability and describes the obtainment process. This formulation combines the therapeutic action of meloxicam as an anti-inflammatory and carisoprodol as and analgesic and anti-inflammatory. Administering the two components jointly produces beneficial results which are not seen when the two active components are administered separately.Type: ApplicationFiled: January 19, 2007Publication date: September 13, 2007Applicant: LABORATORIOS SILANES S.A. DE C.V.Inventors: Antonio Santiago Regalado, Sixto Espinoza Leon
-
Patent number: RE46496Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.Type: GrantFiled: April 21, 2016Date of Patent: August 1, 2017Assignee: Laboratorios Silanes S.A. de C.V.Inventor: Jose Manuel Francisco Ochoa Lara